a company, which is involved in real estate investment trusts
Industry PharmaceuticalsGeneric
Loading...
Hims & Hers Health (HIMS, $26) is predicted by A.I.dvisor to decline by to $25.48 or more within the next week. Following its losing streak extending for a consecutive week, HIMS is expected to continue dropping based on similar cases which trended down, making the odds of a Downtrend continuation
The 10-day moving average for HIMS crossed bearishly below the 50-day moving average on October 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HIMS as a result. In 66 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for HIMS turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 36 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
HIMS moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HIMS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for HIMS entered a downward trend on November 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 13 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +5.63% 3-day Advance, the price is estimated to grow further. Considering data from situations where HIMS advanced for three days, in 240 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
HIMS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (18.719) is normal, around the industry mean (6.379). P/E Ratio (-41.935) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (2.624) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (2.686) is also within normal values, averaging (183.387).
The Tickeron Profit vs. Risk Rating rating for this company is 88 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HIMS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. HIMS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Hims & Hers Health, Inc. is a direct-to-consumer health and wellness platform that connects customers with licensed healthcare professionals across the United States and several international markets. The company offers personalized prescription and non-prescription products spanning sexual health, dermatology, mental health, weight management, and hair loss, sold primarily through its websites and mobile app.
Investors follow HIMS for its rapid revenue growth, vertically integrated pharmacy infrastructure, expanding subscriber base, and its push into high-demand categories such as GLP-1 weight-loss treatments and compounded peptide products. Its brand recognition and marketing reach support strong customer acquisition, though profitability, regulatory exposure, and valuation remain central points of debate.
Over the trailing 30 days, HIMS shares fell approximately 18%, declining from about $29.47 to a close near $24.06. The move was punctuated by heightened volatility, including a 9.75% single-day decline in early November amid broad-market weakness.
The quarterly trend has been similarly negative. Over roughly the past three months, the stock declined about 24%, retreating from levels near $31.65 in early August. After reaching higher levels in late August, shares have trended lower in a stair-step pattern, with intermittent rebounds driven by product and policy headlines that were insufficient to reverse the broader downtrend.
The 30-day decline was driven primarily by legal and regulatory overhangs rather than deterioration in the underlying business. Multiple securities class-action filings were announced, covering an alleged class period from August 2025 through July 2026 and citing concerns over privacy practices, subscription billing, and related disclosures, with a lead-plaintiff deadline in early November. Separately, the company has sought to dismiss an outstanding Federal Trade Commission complaint, keeping regulatory risk in focus.
Profitability concerns also weighed on sentiment. While Q2 2026 revenue rose about 38% year over year to $753.2 million, the net loss widened to roughly $86.3 million, highlighting pressure on margins despite robust top-line growth. Heavy short interest, reported near 24%, contributed to amplified downside moves, and a broad equity selloff in early November further pressured shares.
Offsetting these pressures, a federal decision to temporarily allow compounding of certain peptides, including BPC-157 and TB-500, briefly lifted the stock as investors assessed the potential for a new revenue category. The company also launched injectable and oral testosterone treatments and announced it surpassed a three-million-member milestone during the period.
The broader quarterly decline reflects a shift in investor focus from growth to profitability and risk management. Despite strong revenue expansion and subscriber growth, widening net losses, dilution concerns, and persistent regulatory and legal scrutiny have weighed on the stock's valuation.
High expectations around weight-management and peptide offerings have been tempered by questions about margins, competition, and the durability of subscription economics. Sector rotation away from high-multiple growth names and elevated short interest added further downward pressure. The result has been a sustained pullback from late-summer highs, even as company-specific growth metrics continued to improve.
Tickeron's Trending AI Robots section highlights a curated selection of automated trading bots from a broader platform of hundreds of AI-driven strategies covering thousands of tickers. Only the top-performing and most relevant bots appear in this area, with each bot distinguished by its trading strategy, timeframe, and performance metrics. Because bots vary widely in approach and risk profile, the section allows users to compare strategies and identify those aligned with their objectives. The Trending AI Robots page is updated to reflect current market conditions, offering a way to monitor how automated systems are responding to evolving opportunities.
The next earnings report is a key near-term catalyst, with Wall Street consensus projecting meaningful year-over-year revenue growth and a return to positive earnings per share. Investors will likely focus on subscriber growth and retention, margin trajectory, guidance, and any updates on the GLP-1 and peptide businesses.
Beyond earnings, the resolution or progression of the FTC matter and related securities litigation will remain important sentiment drivers. Commentary from analysts on the peptide opportunity, competitive dynamics in weight management, macroeconomic conditions affecting high-growth equities, and changes in short interest could also influence the stock's direction. These factors present both opportunities and risks, and market participants should monitor developments as they unfold.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.